9,003 Shares in DexCom, Inc. (NASDAQ:DXCM) Bought by Point72 Hong Kong Ltd

Point72 Hong Kong Ltd bought a new position in DexCom, Inc. (NASDAQ:DXCM - Free Report) during the fourth quarter, according to the company in its most recent filing with the SEC. The firm bought 9,003 shares of the medical device company's stock, valued at approximately $700,000.

Other hedge funds have also recently modified their holdings of the company. Geode Capital Management LLC boosted its stake in shares of DexCom by 0.6% during the 4th quarter. Geode Capital Management LLC now owns 9,993,698 shares of the medical device company's stock valued at $775,256,000 after purchasing an additional 56,094 shares in the last quarter. Jennison Associates LLC lifted its stake in shares of DexCom by 10.3% in the fourth quarter. Jennison Associates LLC now owns 7,643,757 shares of the medical device company's stock worth $594,455,000 after buying an additional 710,858 shares in the last quarter. Norges Bank bought a new position in shares of DexCom in the fourth quarter worth approximately $385,367,000. Northern Trust Corp lifted its stake in shares of DexCom by 22.2% in the fourth quarter. Northern Trust Corp now owns 4,146,249 shares of the medical device company's stock worth $322,454,000 after buying an additional 753,857 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of DexCom by 3.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,825,206 shares of the medical device company's stock valued at $219,716,000 after purchasing an additional 91,051 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company's stock.

DexCom Stock Performance

DXCM stock traded down $0.42 during trading on Thursday, reaching $84.48. The company had a trading volume of 447,362 shares, compared to its average volume of 4,347,470. The firm has a 50-day simple moving average of $72.99 and a 200-day simple moving average of $77.92. The company has a market cap of $33.12 billion, a price-to-earnings ratio of 59.12, a price-to-earnings-growth ratio of 2.30 and a beta of 1.43. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. DexCom, Inc. has a twelve month low of $57.52 and a twelve month high of $131.76.

DexCom (NASDAQ:DXCM - Get Free Report) last released its earnings results on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). The company had revenue of $1.04 billion during the quarter, compared to analyst estimates of $1.02 billion. DexCom had a return on equity of 30.14% and a net margin of 14.29%. The firm's revenue for the quarter was up 12.5% on a year-over-year basis. During the same quarter last year, the business earned $0.32 earnings per share. As a group, sell-side analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current year.

Insider Buying and Selling at DexCom

In other DexCom news, EVP Michael Jon Brown sold 13,000 shares of DexCom stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $914,940.00. Following the completion of the sale, the executive vice president now directly owns 105,602 shares in the company, valued at approximately $7,432,268.76. The trade was a 10.96% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Jereme M. Sylvain sold 7,000 shares of DexCom stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $73.83, for a total transaction of $516,810.00. Following the sale, the executive vice president now owns 135,482 shares of the company's stock, valued at approximately $10,002,636.06. The trade was a 4.91% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 66,926 shares of company stock worth $4,734,384. Company insiders own 0.32% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have commented on DXCM. Morgan Stanley upped their target price on shares of DexCom from $75.00 to $82.00 and gave the company an "equal weight" rating in a report on Friday, February 14th. Piper Sandler dropped their target price on shares of DexCom from $100.00 to $90.00 and set an "overweight" rating for the company in a research report on Friday, May 2nd. Barclays increased their price objective on shares of DexCom from $90.00 to $93.00 and gave the company an "equal weight" rating in a research report on Monday, May 5th. Redburn Atlantic upgraded shares of DexCom from a "neutral" rating to a "buy" rating and raised their target price for the stock from $85.00 to $115.00 in a report on Monday, February 3rd. Finally, Robert W. Baird cut their target price on shares of DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a research report on Friday, May 2nd. Five analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $98.11.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.